AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04928651 — intervention group
Intervention type: DRUG
Intervention: Clonidine
Description: Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG.
Study NCT02907112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meat reduction
Description: Advice, Motivational material and food products provided to participants
Study NCT01877707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: home monitoring
Description: Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
Study NCT02545998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telehealthcare
Description: Telephone consultation plus e-mail with attached PAAP and video link
Study NCT03029520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation with iRoot SP sealer
Description: Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
Study NCT03029520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation with AH Plus Sealer
Description: Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
Study NCT01924871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane with remifentanil
Description: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
Study NCT01924871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
Study NCT00492089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00492089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT00492089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Study NCT00492089 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: magnetic resonance imaging
Study NCT03406819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside Sodium
Description: Intracoronary infusion 50\~100μg each time (repeated)
Study NCT00492089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT03406819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Intracoronary infusion 10μg/kg for single time
Study NCT03406819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparinized saline
Description: Intracoronary infusion 2ml for single time
Study NCT00492089 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Study NCT02486796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reishi mushroom extract
Description: Reishi mushroom preparation produced water-ethanol extraction.
Study NCT02486796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Preparation of coenzyme Q10
Study NCT02486796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Preparation of melatonin
Study NCT02687009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
Study NCT01037842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks
Study NCT01037842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo three times a day added to metformin 500 mg three times a day for 16 weeks
Study NCT04123925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
Study NCT01075932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil
Description: Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
Study NCT01075932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g placebo (olive oil) taken daily for 12 weeks
Study NCT03705195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
Study NCT04736264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual rehabilitation module: navigation and mobility
Description: The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
Study NCT04736264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual rehabilitation module: exercise
Description: An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
Study NCT04736264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual rehabilitation module: reading
Description: Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
Study NCT01874951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
Study NCT01874951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
Study NCT00798551 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Risk counseling
Description: cardiovascular risk counseling regarding elevated blood pressure
Study NCT01752348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin, US standard reference E.coli
Study NCT01752348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin, US standard reference E.coli
Study NCT02308072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
Study NCT02308072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 35 mg/m\^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m\^2)
Study NCT05915052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-type suture ileostomy
Description: Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
Study NCT05915052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the traditional ileostomy
Description: Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
Study NCT03092908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mature vinegar
Description: Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
Study NCT03092908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (water)
Description: Administer 5 ml placebo (water) three times a day.
Study NCT02308072 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
Study NCT00555464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
Study NCT00555464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisolone given at 3 mg/kg/day by mouth for 12 week
Study NCT02237612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI
Study NCT02237612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02660281 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation 1200 cGy
Description: 1200 cGy TBI in 8 fractions
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pre-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given prior to the stem cell infusion
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pre-Stem Cell Infusion Mesna
Description: Mesna given prior to the stem cell infusion
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Melphalan
Study NCT02660281 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Infusion
Description: Stem cell infusion
Study NCT00687570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fresubin Energy Drink
Description: Fresubin energy drink 30 kcal/kg\*dag-1, seven days before surgery
Study NCT00687570 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Laxabon®
Description: Laxabon® 4 litres starting the day before surgery
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Cyclophosphamide
Description: Cyclophosphamide given after the stem cell infusion
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Post-Stem Cell Infusion Mesna
Description: Mesna given after the Stem Cell Infusion
Study NCT02660281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Thiotepa
Study NCT01207570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endermotherapy
Description: The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
Study NCT01207570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive manual stretching
Description: The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
Study NCT03127722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
Study NCT03127722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
Study NCT03127722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESSURE (BAY1454032)
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
Study NCT03127722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic tubal sterilization
Description: Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
Study NCT01728519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT SC
Description: AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
Study NCT01728519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT ID
Description: AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
Study NCT01728519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
Study NCT01728519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ID
Description: Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
Study NCT01972633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Endovenous Laser (1470nm) ablation of great or small saphenous vein
Study NCT01972633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
Study NCT00992667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin nebulization
Description: 6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
Study NCT00508261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection
Study NCT00508261 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection
Study NCT00508261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Single dose intramuscular injection
Study NCT00508261 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Single dose intramuscular injection
Study NCT00508261 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: Single dose intramuscular injection
Study NCT00873418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training
Description: 16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
Study NCT00873418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping skills training
Description: 16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
Study NCT01544998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: 10 ug/kg
Study NCT01544998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg
Study NCT01544998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
Study NCT01544998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline load
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
Study NCT04577677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: tDCS and peripheral nerve stimulation
Study NCT03056482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
Study NCT03056482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.05mg/kg
Description: Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
Study NCT03056482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.1mg/kg
Description: Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
Study NCT04440176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Neisseria meningitidis group A, B, C, W, and Y vaccine
Study NCT04440176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study NCT03626779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prf
Description: Take 10cc blood from patient and gain prf blug
Study NCT01103310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9392
Study NCT03517553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS users in ESRD
Description: use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
Study NCT05545982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video laryngoscope with Miller approach
Description: Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
Study NCT02388503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no added fruit extract
Study NCT02388503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruit extract
Study NCT00598026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele- follow-up
Description: Remote transmission to the implantation centre every 3 months
Study NCT00598026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional follow-up
Description: Visits at the implantation centre every 3 months
Study NCT01364870 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working.